ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000613

Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration

Identifieur interne : 000613 ( PascalFrancis/Curation ); précédent : 000612; suivant : 000614

Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration

Auteurs : Brian N. Mathur [États-Unis] ; M. Diana Neely [États-Unis] ; Melanie Dyllick-Brenzinger [Canada] ; Anurag Tandon [Canada] ; Ariel Y. Deutch [États-Unis]

Source :

Brain research [ 0006-8993 ] ; 2007.

RBID : Pascal:07-0476981

Descripteurs français

Pascal (Inist)
- Multicatalytic endopeptidase complex, Voie nigrostriatale, Dopamine, Dégénérescence, Corps strié, Locus niger, Tyrosine 3-monooxygenase, Parkinson maladie, Rat, Inhibiteur enzyme, Animal.

English descriptors

KwdEn :
- Animal, Corpus striatum, Degeneration, Dopamine, Enzyme inhibitor, Locus niger, Multicatalytic endopeptidase complex, Nigrostriatal pathway, Parkinson disease, Rat, Tyrosine 3-monooxygenase.

Abstract

Proteasomal dysfunction has been suggested to contribute to the degeneration of nigrostriatal dopamine neurons in Parkinson's disease. A recent study reported that systemic treatment of rats with the proteasome inhibitor Z-lle-Glu(OtBu)-Ala-Leu-al (PSI) causes a slowly progressive degeneration of nigrostriatal dopamine neurons, the presence of inclusion bodies in dopamine neurons, and motor impairment. We examined in vitro and in uiuo the effects of PSI on nigrostriatal dopamine neurons. Mass spectrometric analysis was employed to verify the authenticity of the PSI compound. PSI was non-specifically toxic to neurons in ventral mesencephalic organotypic slice cultures, indicating that impairment of proteasome function in vitro is toxic. Moreover, systemic administration of PSI transiently decreased brain proteasome activity. Systemic treatment of rats with PSI did not, however, result in any biochemical or anatomical evidence of lesions of nigrostriatal dopamine neurons, nor were any changes in locomotor activity observed. These data suggest that systemic administration of proteasome inhibitors to normal adult rats does not reliably cause an animal model ofparkinsonism.

A01	`01`	`1`		`@0 0006-8993`
A02	`01`			`@0 BRREAP`
A03		`1`		`@0 Brain res.`
A05				`@2 1168`
A08	`01`	`1`	`ENG`	`@1 Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration`
A11	`01`	`1`		`@1 MATHUR (Brian N.)`
A11	`02`	`1`		`@1 NEELY (M. Diana)`
A11	`03`	`1`		`@1 DYLLICK-BRENZINGER (Melanie)`
A11	`04`	`1`		`@1 TANDON (Anurag)`
A11	`05`	`1`		`@1 DEUTCH (Ariel Y.)`
A14	`01`			`@1 Program in Neuroscience and Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center @2 Nashville, TN @3 USA @Z 1 aut. @Z 2 aut. @Z 5 aut.`
A14	`02`			`@1 Center for Research in Neurodegenerative Diseases, University of Toronto @2 Toronto, Ontario @3 CAN @Z 3 aut. @Z 4 aut.`
A20				`@1 83-89`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 12895 @5 354000149761700100`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 3/4 p.`
A47	`01`	`1`		`@0 07-0476981`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Brain research`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Proteasomal dysfunction has been suggested to contribute to the degeneration of nigrostriatal dopamine neurons in Parkinson's disease. A recent study reported that systemic treatment of rats with the proteasome inhibitor Z-lle-Glu(OtBu)-Ala-Leu-al (PSI) causes a slowly progressive degeneration of nigrostriatal dopamine neurons, the presence of inclusion bodies in dopamine neurons, and motor impairment. We examined in vitro and in uiuo the effects of PSI on nigrostriatal dopamine neurons. Mass spectrometric analysis was employed to verify the authenticity of the PSI compound. PSI was non-specifically toxic to neurons in ventral mesencephalic organotypic slice cultures, indicating that impairment of proteasome function in vitro is toxic. Moreover, systemic administration of PSI transiently decreased brain proteasome activity. Systemic treatment of rats with PSI did not, however, result in any biochemical or anatomical evidence of lesions of nigrostriatal dopamine neurons, nor were any changes in locomotor activity observed. These data suggest that systemic administration of proteasome inhibitors to normal adult rats does not reliably cause an animal model ofparkinsonism.
C02	`01`	`X`		`@0 002B17G`
C02	`02`	`X`		`@0 002B18C13`
C03	`01`	`X`	`FRE`	`@0 Multicatalytic endopeptidase complex @2 FE @5 01`
C03	`01`	`X`	`ENG`	`@0 Multicatalytic endopeptidase complex @2 FE @5 01`
C03	`01`	`X`	`SPA`	`@0 Multicatalytic endopeptidase complex @2 FE @5 01`
C03	`02`	`X`	`FRE`	`@0 Voie nigrostriatale @5 02`
C03	`02`	`X`	`ENG`	`@0 Nigrostriatal pathway @5 02`
C03	`02`	`X`	`SPA`	`@0 Vía nigroestriatal @5 02`
C03	`03`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 03`
C03	`03`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 03`
C03	`03`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 03`
C03	`04`	`X`	`FRE`	`@0 Dégénérescence @5 04`
C03	`04`	`X`	`ENG`	`@0 Degeneration @5 04`
C03	`04`	`X`	`SPA`	`@0 Degeneración @5 04`
C03	`05`	`X`	`FRE`	`@0 Corps strié @5 05`
C03	`05`	`X`	`ENG`	`@0 Corpus striatum @5 05`
C03	`05`	`X`	`SPA`	`@0 Cuerpo estriado @5 05`
C03	`06`	`X`	`FRE`	`@0 Locus niger @5 06`
C03	`06`	`X`	`ENG`	`@0 Locus niger @5 06`
C03	`06`	`X`	`SPA`	`@0 Locus níger @5 06`
C03	`07`	`X`	`FRE`	`@0 Tyrosine 3-monooxygenase @2 FE @5 07 @6 Tyrosine «3»-monooxygenase`
C03	`07`	`X`	`ENG`	`@0 Tyrosine 3-monooxygenase @2 FE @5 07 @6 Tyrosine «3»-monooxygenase`
C03	`07`	`X`	`SPA`	`@0 Tyrosine 3-monooxygenase @2 FE @5 07 @6 Tyrosine «3»-monooxygenase`
C03	`08`	`X`	`FRE`	`@0 Parkinson maladie @5 09`
C03	`08`	`X`	`ENG`	`@0 Parkinson disease @5 09`
C03	`08`	`X`	`SPA`	`@0 Parkinson enfermedad @5 09`
C03	`09`	`X`	`FRE`	`@0 Rat @5 54`
C03	`09`	`X`	`ENG`	`@0 Rat @5 54`
C03	`09`	`X`	`SPA`	`@0 Rata @5 54`
C03	`10`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 57`
C03	`10`	`X`	`ENG`	`@0 Enzyme inhibitor @5 57`
C03	`10`	`X`	`SPA`	`@0 Inhibidor enzima @5 57`
C03	`11`	`X`	`FRE`	`@0 Animal @5 69`
C03	`11`	`X`	`ENG`	`@0 Animal @5 69`
C03	`11`	`X`	`SPA`	`@0 Animal @5 69`
C07	`01`	`X`	`FRE`	`@0 Peptidases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Peptidases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Peptidases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`02`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`02`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`03`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`03`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`04`	`X`	`FRE`	`@0 Oxidoreductases @2 FE`
C07	`04`	`X`	`ENG`	`@0 Oxidoreductases @2 FE`
C07	`04`	`X`	`SPA`	`@0 Oxidoreductases @2 FE`
C07	`05`	`X`	`FRE`	`@0 Encéphale pathologie @5 20`
C07	`05`	`X`	`ENG`	`@0 Cerebral disorder @5 20`
C07	`05`	`X`	`SPA`	`@0 Encéfalo patología @5 20`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central @5 21`
C07	`06`	`X`	`ENG`	`@0 Central nervous system @5 21`
C07	`06`	`X`	`SPA`	`@0 Sistema nervioso central @5 21`
C07	`07`	`X`	`FRE`	`@0 Catécholamine @5 22`
C07	`07`	`X`	`ENG`	`@0 Catecholamine @5 22`
C07	`07`	`X`	`SPA`	`@0 Catecolamina @5 22`
C07	`08`	`X`	`FRE`	`@0 Neurotransmetteur @5 23`
C07	`08`	`X`	`ENG`	`@0 Neurotransmitter @5 23`
C07	`08`	`X`	`SPA`	`@0 Neurotransmisor @5 23`
C07	`09`	`X`	`FRE`	`@0 Maladie dégénérative @5 24`
C07	`09`	`X`	`ENG`	`@0 Degenerative disease @5 24`
C07	`09`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 24`
C07	`10`	`X`	`FRE`	`@0 Système nerveux pathologie @5 25`
C07	`10`	`X`	`ENG`	`@0 Nervous system diseases @5 25`
C07	`10`	`X`	`SPA`	`@0 Sistema nervioso patología @5 25`
C07	`11`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 26`
C07	`11`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 26`
C07	`11`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 26`
C07	`12`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 27`
C07	`12`	`X`	`ENG`	`@0 Central nervous system disease @5 27`
C07	`12`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 27`
C07	`13`	`X`	`FRE`	`@0 Noyau gris central @5 28`
C07	`13`	`X`	`ENG`	`@0 Basal ganglion @5 28`
C07	`13`	`X`	`SPA`	`@0 Núcleo basal @5 28`
C07	`14`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`14`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`14`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`15`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`15`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`15`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`16`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`16`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`16`	`X`	`SPA`	`@0 Vertebrata @2 NS`
N21				`@1 309`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000707

Links to Exploration step

Pascal:07-0476981

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration</title>
<author><name sortKey="Mathur, Brian N" sort="Mathur, Brian N" uniqKey="Mathur B" first="Brian N." last="Mathur">Brian N. Mathur</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Program in Neuroscience and Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center</s1>
<s2>Nashville, TN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Neely, M Diana" sort="Neely, M Diana" uniqKey="Neely M" first="M. Diana" last="Neely">M. Diana Neely</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Program in Neuroscience and Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center</s1>
<s2>Nashville, TN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dyllick Brenzinger, Melanie" sort="Dyllick Brenzinger, Melanie" uniqKey="Dyllick Brenzinger M" first="Melanie" last="Dyllick-Brenzinger">Melanie Dyllick-Brenzinger</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Center for Research in Neurodegenerative Diseases, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Tandon, Anurag" sort="Tandon, Anurag" uniqKey="Tandon A" first="Anurag" last="Tandon">Anurag Tandon</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Center for Research in Neurodegenerative Diseases, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Deutch, Ariel Y" sort="Deutch, Ariel Y" uniqKey="Deutch A" first="Ariel Y." last="Deutch">Ariel Y. Deutch</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Program in Neuroscience and Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center</s1>
<s2>Nashville, TN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0476981</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0476981 INIST</idno>
<idno type="RBID">Pascal:07-0476981</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000707</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000613</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration</title>
<author><name sortKey="Mathur, Brian N" sort="Mathur, Brian N" uniqKey="Mathur B" first="Brian N." last="Mathur">Brian N. Mathur</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Program in Neuroscience and Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center</s1>
<s2>Nashville, TN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Neely, M Diana" sort="Neely, M Diana" uniqKey="Neely M" first="M. Diana" last="Neely">M. Diana Neely</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Program in Neuroscience and Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center</s1>
<s2>Nashville, TN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dyllick Brenzinger, Melanie" sort="Dyllick Brenzinger, Melanie" uniqKey="Dyllick Brenzinger M" first="Melanie" last="Dyllick-Brenzinger">Melanie Dyllick-Brenzinger</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Center for Research in Neurodegenerative Diseases, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Tandon, Anurag" sort="Tandon, Anurag" uniqKey="Tandon A" first="Anurag" last="Tandon">Anurag Tandon</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Center for Research in Neurodegenerative Diseases, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Deutch, Ariel Y" sort="Deutch, Ariel Y" uniqKey="Deutch A" first="Ariel Y." last="Deutch">Ariel Y. Deutch</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Program in Neuroscience and Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center</s1>
<s2>Nashville, TN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Corpus striatum</term>
<term>Degeneration</term>
<term>Dopamine</term>
<term>Enzyme inhibitor</term>
<term>Locus niger</term>
<term>Multicatalytic endopeptidase complex</term>
<term>Nigrostriatal pathway</term>
<term>Parkinson disease</term>
<term>Rat</term>
<term>Tyrosine 3-monooxygenase</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Multicatalytic endopeptidase complex</term>
<term>Voie nigrostriatale</term>
<term>Dopamine</term>
<term>Dégénérescence</term>
<term>Corps strié</term>
<term>Locus niger</term>
<term>Tyrosine 3-monooxygenase</term>
<term>Parkinson maladie</term>
<term>Rat</term>
<term>Inhibiteur enzyme</term>
<term>Animal</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Proteasomal dysfunction has been suggested to contribute to the degeneration of nigrostriatal dopamine neurons in Parkinson's disease. A recent study reported that systemic treatment of rats with the proteasome inhibitor Z-lle-Glu(OtBu)-Ala-Leu-al (PSI) causes a slowly progressive degeneration of nigrostriatal dopamine neurons, the presence of inclusion bodies in dopamine neurons, and motor impairment. We examined in vitro and in uiuo the effects of PSI on nigrostriatal dopamine neurons. Mass spectrometric analysis was employed to verify the authenticity of the PSI compound. PSI was non-specifically toxic to neurons in ventral mesencephalic organotypic slice cultures, indicating that impairment of proteasome function in vitro is toxic. Moreover, systemic administration of PSI transiently decreased brain proteasome activity. Systemic treatment of rats with PSI did not, however, result in any biochemical or anatomical evidence of lesions of nigrostriatal dopamine neurons, nor were any changes in locomotor activity observed. These data suggest that systemic administration of proteasome inhibitors to normal adult rats does not reliably cause an animal model ofparkinsonism.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-8993</s0>
</fA01>
<fA02 i1="01"><s0>BRREAP</s0>
</fA02>
<fA03 i2="1"><s0>Brain res.</s0>
</fA03>
<fA05><s2>1168</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MATHUR (Brian N.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>NEELY (M. Diana)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DYLLICK-BRENZINGER (Melanie)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TANDON (Anurag)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DEUTCH (Ariel Y.)</s1>
</fA11>
<fA14 i1="01"><s1>Program in Neuroscience and Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center</s1>
<s2>Nashville, TN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Center for Research in Neurodegenerative Diseases, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>83-89</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>12895</s2>
<s5>354000149761700100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>3/4 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0476981</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Brain research</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Proteasomal dysfunction has been suggested to contribute to the degeneration of nigrostriatal dopamine neurons in Parkinson's disease. A recent study reported that systemic treatment of rats with the proteasome inhibitor Z-lle-Glu(OtBu)-Ala-Leu-al (PSI) causes a slowly progressive degeneration of nigrostriatal dopamine neurons, the presence of inclusion bodies in dopamine neurons, and motor impairment. We examined in vitro and in uiuo the effects of PSI on nigrostriatal dopamine neurons. Mass spectrometric analysis was employed to verify the authenticity of the PSI compound. PSI was non-specifically toxic to neurons in ventral mesencephalic organotypic slice cultures, indicating that impairment of proteasome function in vitro is toxic. Moreover, systemic administration of PSI transiently decreased brain proteasome activity. Systemic treatment of rats with PSI did not, however, result in any biochemical or anatomical evidence of lesions of nigrostriatal dopamine neurons, nor were any changes in locomotor activity observed. These data suggest that systemic administration of proteasome inhibitors to normal adult rats does not reliably cause an animal model ofparkinsonism.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B18C13</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Multicatalytic endopeptidase complex</s0>
<s2>FE</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Multicatalytic endopeptidase complex</s0>
<s2>FE</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Multicatalytic endopeptidase complex</s0>
<s2>FE</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Voie nigrostriatale</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nigrostriatal pathway</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vía nigroestriatal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dégénérescence</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Degeneration</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Degeneración</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Corps strié</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Corpus striatum</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cuerpo estriado</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Locus niger</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Locus niger</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Locus níger</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Tyrosine 3-monooxygenase</s0>
<s2>FE</s2>
<s5>07</s5>
<s6>Tyrosine «3»-monooxygenase</s6>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Tyrosine 3-monooxygenase</s0>
<s2>FE</s2>
<s5>07</s5>
<s6>Tyrosine «3»-monooxygenase</s6>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tyrosine 3-monooxygenase</s0>
<s2>FE</s2>
<s5>07</s5>
<s6>Tyrosine «3»-monooxygenase</s6>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Rat</s0>
<s5>54</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Rat</s0>
<s5>54</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Rata</s0>
<s5>54</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>57</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>57</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>57</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Animal</s0>
<s5>69</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Animal</s0>
<s5>69</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Animal</s0>
<s5>69</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>20</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>20</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>20</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>21</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>21</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>21</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>22</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>22</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>22</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>23</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>23</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>23</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>24</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>24</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>24</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>25</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>25</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>25</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>26</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>26</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>26</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>27</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>27</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>27</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Noyau gris central</s0>
<s5>28</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Basal ganglion</s0>
<s5>28</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Núcleo basal</s0>
<s5>28</s5>
</fC07>
<fC07 i1="14" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="14" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="14" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="15" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="15" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="15" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="16" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="16" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="16" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>309</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000613 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000613 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:07-0476981
   |texte=   Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration

Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri